Healthcare Industry News: Dupuytren's contracture
News Release - May 15, 2007
HealthSonix Develops New Treatment Protocols for Dupuytren's Contracture; Patients Show Positive Results
IRVINE, CA--(Healthcare Sales & Marketing Network)--May 15, 2007 -- HealthSonix, Inc. (Other OTC:HSXI.PK ) (Frankfurt:H7S.F ) today announced that it has achieved successful results in the treatment of patients with Dupuytren's contracture using its sound pulse technology.Dupuytren's contracture, a disease of the palmar fascia, results in the thickening and shortening of fibrous bands in the hands and fingers. The incidence of Dupuytren's contracture is highest in Caucasians, historically those of Celtic descent. It most often affects the ring or little finger, sometimes both, and often in both hands. Although the exact cause is unknown it is genetic in nature, meaning it runs in families. This condition is seven times more common in men than women. The disorder may occur suddenly but more commonly progresses slowly over a period of years. The disease usually doesn't cause symptoms until after the age of 40.
Without treatment, such as surgical intervention, the Contracture can become so severe that the patient cannot straighten his/her finger, and eventually they may not be able to use their hand effectively.
"We were quite pleasantly surprised by the fact that our sound pulses were able to relieve some of the stiffness and in some cases even restore mobility," said Dr. David Venturi, Medical Director of HealthSonix. "More clinical work will commence shortly to further study and expand on treatment outcomes," added Dr. Venturi.
HealthSonix sound pulse technology has now been made available for home use in the state of the art, self-administered enSonix@home medical device. The enSonix@home device will be available online May 22, 2007, when the company launches its new online store: www.MyArthritisStore.com
HealthSonix, Inc. (Other OTC:HSXI.PK ) (Frankfurt:H7S.F ) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Source: HealthSonix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
